Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Blood (2024) 143 (20): 2053–2058.

https://doi.org/10.1182/blood.2023021184

Published: 2024

Includes: Supplemental data

Journal Articles

The Identification and Characterization of Retrospective Cohorts of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the United States

Catherine Broome, Joseph Patrick Catlett, Daniel J Hausrath, Rahul Shah, Jacob Lai, Kathy Dong, Jon Fryzek, Meghan Mitchell, Lauren Bylsma, Loren Lipworth, Todd Edwards, Nawar Shara, Stephen Fernandez, Naval Daver, Carl E Allen

Blood (2023) 142 (Supplement 1): 5357.

https://doi.org/10.1182/blood-2023-180249

Published: 2023

Journal Articles

Identification of Germline, Ancestry-Specific Variants for Langerhans Cell Histiocytosis in Hispanic Patients

Priya Bhatia Shetty, Erin Peckham-Gregory, Erik Stricker, Howard Lin, Brooks Scull, Erik Ehli, Christel Davis, Kenneth L. McClain, Philip J. Lupo, Carl E Allen, Michael E. Scheurer

Blood (2023) 142 (Supplement 1): 4581.

https://doi.org/10.1182/blood-2023-191003

Published: 2023

Journal Articles

Expanded Assessments of Germline Genetic Variants Identify Additional Risk Loci for Langerhans Cell Histiocytosis

Erin Peckham-Gregory, Priya Bhatia Shetty, Erik Stricker, Danielle Mitchell, Howard Lin, Brooks Scull, Erik Ehli, Christel Davis, Kenneth L. McClain, Philip J. Lupo, Carl E Allen, Michael E. Scheurer

Blood (2023) 142 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2023-189670

Published: 2023

Journal Articles

Safe and Effective Escalation of Evidence-Based Chemotherapy for Mature B Cell Non-Hodgkin's Lymphoma in a Low Resource Setting

Anne Akullo, Ruth Namazzi, Peter Wasswa, Casey Lee McAtee, Moureen Nanvuma, Hellen Alamo, Hellen Mugarra Kabawheza, Joseph Lubega, Carl E Allen

Blood (2023) 142 (Supplement 1): 1753.

https://doi.org/10.1182/blood-2023-190794

Published: 2023

Journal Articles

Evaluation of Safety and Efficacy of Ruxolitinib in Patients with Pediatric Lymphoproliferative Disorders

Daria Vakula, Ashley Reiland, Ivan Kingyue Chinn, Sandra Andrea Salinas, Alexander Patlan Nieto, Lisa Forbes Satter, Carl E Allen

Blood (2023) 142 (Supplement 1): 2553.

https://doi.org/10.1182/blood-2023-190752

Published: 2023

Journal Articles

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Abhishek Maiti, Naval Daver, Swami P. Iyer, David McCall, Satyen H Gohil, Javier Lopez Jimenez, Hayley Lane, Benjamin Kim, Kim-Hien Dao, Gary Patou, Sandip Panicker, Kelly Covert, Graham Carl Parry, Carl E Allen

Blood (2023) 142 (Supplement 1): 1162.

https://doi.org/10.1182/blood-2023-177795

Published: 2023

Journal Articles

HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes

Peter Dimitrion, Jugmohit Toor, James Ge, Qiyan Wang, Carl E Allen, Li Zhou, Qing-Sheng Mi

Blood (2023) 142 (Supplement 1): 676.

https://doi.org/10.1182/blood-2023-185195

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes Among Patients with Secondary Hemophagocytic Lymphohistiocytosis Treated with Emapalumab in the United States: The Real-HLH Study

Carl E Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly Walkovich, John Yee

Blood (2023) 142 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2023-186948

Published: 2023

Journal Articles

Responses to Combination Chemotherapy with MAPK Pathway Inhibition in Relapsed and Refractory LCH

Vivekanudeep Karri, Nader Kim El-Mallawany, Howard Lin, Harshal A Abhyankar, Jennifer Elise Agrusa, Jessica Velazquez, Olive S. Eckstein, Nitya Gulati, Carl E Allen, Kenneth L. McClain

Blood (2023) 142 (Supplement 1): 6349.

https://doi.org/10.1182/blood-2023-190403

Published: 2023

Journal Articles

Retrospective Analysis of Clofarabine Salvage Therapy in Refractory Multifocal Langerhans Cell Histiocytosis (LCH)

Deevyashali Parekh, Howard Lin, Kenneth L. McClain, Nitya Gulati, Olive S. Eckstein, Nader Kim El-Mallawany, Jennifer Elise Agrusa, Carl E Allen

Blood (2023) 142 (Supplement 1): 4574.

https://doi.org/10.1182/blood-2023-184714

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes Among Patients with Primary Hemophagocytic Lymphohistiocytosis with and without Infection at Diagnosis and Treated with Emapalumab: The Real-HLH Study

Carl E Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly Walkovich, John Yee

Blood (2023) 142 (Supplement 1): 2534.

https://doi.org/10.1182/blood-2023-181777

Published: 2023

Journal Articles

Feasibility of a Dose-Intensive Regimen for Pediatric Burkitt Lymphoma in Malawi

Rizine R Mzikamanda, II, Loviisa Mulanje, Apatsa Matatiyo, Zoe Mwale, Gugulethu Mapurisa, Ruth Namazzi, Nader Kim El-Mallawany, Casey Lee McAtee, Katherine Douglas Westmoreland, Carl E Allen, Nmazuo Ozuah

Blood (2023) 142 (Supplement 1): 4509.

https://doi.org/10.1182/blood-2023-185302

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Journal Articles

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study

Carl E. Allen, Shanmuganathan Chandrakasan, Michael B Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly J. Walkovich, John Yee

Blood (2022) 140 (Supplement 1): 2595–2596.

https://doi.org/10.1182/blood-2022-166649

Published: 2022

Journal Articles

Bone Marrow-Derived BRAFV600E-Mutated Cells Drive Neurodegeneration in a Mouse Model of Langerhans Cell Histiocytosis

C. Matthias Wilk, Jessica LeBerichel, Flurin Cathomas, George Heaton, Orsolya Török, Aymeric Silvin, Zhenyu Yue, Scott Russo, Florent Ginhoux, Jennifer Picarsic, Carl E. Allen, Miriam Merad

Blood (2022) 140 (Supplement 1): 3873.

https://doi.org/10.1182/blood-2022-169842

Published: 2022

Journal Articles

Myeloid Progenitors Define Extent of Disease in Mouse Models of Histiocytic Disorders: BRAF V600E Expression in Monocyte Lineage Recapitulates Erdheim-Chester Phenotype

C. Matthias Wilk, Brooks Scull, Ryan Fleischmann, Tsz-Kwong Man, Kenneth L. McClain, Miriam Merad, Florent Ginhoux, Carl E. Allen

Blood (2022) 140 (Supplement 1): 9597.

https://doi.org/10.1182/blood-2022-168116

Published: 2022

Journal Articles

Identification and Characterization of a Retrospective Cohort of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the US

Catherine M. Broome, Jon P. Fryzek, Lauren C. Bylsma, Meghan E. Mitchell, Nawar M. Shara, Stephen J. Fernandez, Joseph P. Catlett, Todd L. Edwards, Daniel J. Hausrath, Loren P. Lipworth, Jacob S. Lai, Kathy Dong, Naval Daver, Carl E. Allen

Blood (2022) 140 (Supplement 1): 5490–5491.

https://doi.org/10.1182/blood-2022-167819

Published: 2022

Journal Articles

Fine-Mapping of SMAD6 Sequence Data Identifies Additional Putative Risk Loci for Langerhans Cell Histiocytosis

Erin Peckham-Gregory, Priya B Shetty, Howard Lin, Brooks Scull, Erik Ehli, Kenneth L. McClain, Philip J. Lupo, Carl E. Allen, Michael E. Scheurer

Blood (2022) 140 (Supplement 1): 3953–3954.

https://doi.org/10.1182/blood-2022-170418

Published: 2022

Journal Articles

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Adi Zoref-Lorenz, David C. Fajgenbaum, Sheila K. Pierson, Abiola Oladapo, John Yee, Nitya Gulati, Carl E. Allen, Michael B. Jordan

Blood (2022) 140 (Supplement 1): 11170–11171.

https://doi.org/10.1182/blood-2022-170288

Published: 2022

NARROW

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

The Identification and Characterization of Retrospective Cohorts of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the United States

Identification of Germline, Ancestry-Specific Variants for Langerhans Cell Histiocytosis in Hispanic Patients

Expanded Assessments of Germline Genetic Variants Identify Additional Risk Loci for Langerhans Cell Histiocytosis

Safe and Effective Escalation of Evidence-Based Chemotherapy for Mature B Cell Non-Hodgkin's Lymphoma in a Low Resource Setting

Evaluation of Safety and Efficacy of Ruxolitinib in Patients with Pediatric Lymphoproliferative Disorders

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

HDAC3 Is Required for Pathognomonic Features of Langerhans Cell Histiocytes

Real-World Treatment Patterns and Outcomes Among Patients with Secondary Hemophagocytic Lymphohistiocytosis Treated with Emapalumab in the United States: The Real-HLH Study

Responses to Combination Chemotherapy with MAPK Pathway Inhibition in Relapsed and Refractory LCH

Retrospective Analysis of Clofarabine Salvage Therapy in Refractory Multifocal Langerhans Cell Histiocytosis (LCH)

Real-World Treatment Patterns and Outcomes Among Patients with Primary Hemophagocytic Lymphohistiocytosis with and without Infection at Diagnosis and Treated with Emapalumab: The Real-HLH Study

Feasibility of a Dose-Intensive Regimen for Pediatric Burkitt Lymphoma in Malawi

Genomic profiling for clinical decision making in lymphoid neoplasms

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study

Bone Marrow-Derived BRAFV600E-Mutated Cells Drive Neurodegeneration in a Mouse Model of Langerhans Cell Histiocytosis

Myeloid Progenitors Define Extent of Disease in Mouse Models of Histiocytic Disorders: BRAF V600E Expression in Monocyte Lineage Recapitulates Erdheim-Chester Phenotype

Identification and Characterization of a Retrospective Cohort of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the US

Fine-Mapping of SMAD6 Sequence Data Identifies Additional Putative Risk Loci for Langerhans Cell Histiocytosis

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only